WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596566
CAS#: 34522-46-8 (fumarate)
Description: Oxetorone fumarate is a serotonin antagonist, antihistamine, and alpha blocker used as an antimigraine drug.
MedKoo Cat#: 596566
Name: Oxetorone fumarate
CAS#: 34522-46-8 (fumarate)
Chemical Formula: C25H25NO6
Exact Mass:
Molecular Weight: 435.47
Elemental Analysis: C, 68.95; H, 5.79; N, 3.22; O, 22.04
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 26020-55-3 (free base); 34522-46-8 (fumarate)
Synonym: Oxetorone fumarate; Nocertone; L 6257; L-6257; L6257;
IUPAC/Chemical Name: (Z)-1-(benzo[6,7]oxepino[4,3-b]benzofuran-6(12H)-ylidene)-N,N-dimethylpropan-1-amine fumarate
InChi Key: PLDLFFXDBRGESH-SMMGVUOFSA-N
InChi Code: InChI=1S/C21H21NO2.C4H4O4/c1-4-17(22(2)3)20-15-10-6-7-11-18(15)23-13-16-14-9-5-8-12-19(14)24-21(16)20;5-3(6)1-2-4(7)8/h5-12H,4,13H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b20-17-;2-1+
SMILES Code: CC/C(N(C)C)=C1C(OC2=CC=CC=C23)=C3COC4=CC=CC=C/14.O=C(O)/C=C/C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 435.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Deguigne M, Bruneau C, Touré A, Turcant A, Le Roux G. New evidence for oxetorone toxicity. Clin Toxicol (Phila). 2017 Feb;55(2):142-146. doi: 10.1080/15563650.2016.1267358. Epub 2016 Dec 14. PubMed PMID: 27967233.
2: Fathallah N, Chatti S, Azouz MM. [Lymphocytic colitis associated with oxetorone consumption]. Gastroenterol Clin Biol. 2010 Feb;34(2):154-5. doi: 10.1016/j.gcb.2009.12.001. Epub 2010 Jan 21. French. PubMed PMID: 20096517.
3: Ducros A. [National ranking exam. N64. What could fall at the exam?]. Rev Prat. 2008 Mar 15;58(5):549-50. French. PubMed PMID: 18524114.
4: Payen C, Patat AM, Pulce C, Descotes J. [Acute poisoning with oxetorone]. Therapie. 2006 Nov-Dec;61(6):548-50. French. PubMed PMID: 17348615.
5: Massiou H, Bousser MG. [Prophylactic drug treatment of migraine]. Rev Neurol (Paris). 2005 Jul;161(6-7):681-4. Review. French. PubMed PMID: 16141958.
6: Géraud G, Lantéri-Minet M, Lucas C, Valade D; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004 Aug;26(8):1305-18. PubMed PMID: 15476911.
7: Pradalier A, Molitor JL, Campinos C. [Oxetorone and profuse sweating]. Therapie. 2003 Mar-Apr;58(2):166-7. French. PubMed PMID: 12942859.
8: Macaigne G, Boivin JF, Chayette C, Cheaib S, Deplus R. [Oxetorone-associated lymphocytic colitis]. Gastroenterol Clin Biol. 2002 May;26(5):537. French. PubMed PMID: 12122372.
9: Massiou H. [Prophylactic treatments of migraine]. Rev Neurol (Paris). 2000;156 Suppl 4:4S79-86. Review. French. PubMed PMID: 11139754.
10: Pradalier A. Hyperprolactinaemia and depression induced by oxetorone. Cephalalgia. 1996 Dec;16(8):560-1. PubMed PMID: 8980859.
11: Ollat H. [Serotonin agonists and antagonists in migraine]. Pathol Biol (Paris). 1992 Apr;40(4):389-96. Review. French. PubMed PMID: 1353874.
12: Richardet JP, Lons T, Mal F, Trinchet JC. [Chronic diarrhea under treatment with oxetorone]. Gastroenterol Clin Biol. 1992;16(1):100. French. PubMed PMID: 1537471.
13: Galerneau V, Petit J, Deghmani M, Leroy J, Droy JM, Leroy A, Oksenhendler G, Winckler C. Severe self-poisoning with oxetorone: report of one case. J Toxicol Clin Toxicol. 1990;28(1):111-6. PubMed PMID: 2381017.
14: Massiou H, Bousser MG. [Antimigrainous agents used in maintenance treatment]. Rev Prat. 1986 Jan 21;36(5):199-204. French. PubMed PMID: 2870558.
15: Barchewitz G, Vernant C, Mazue G, Binon F, Cier A, Tuchmann Duplessis H. Oxetorone-induced hyperprogesteronemia and the development of uterine decidual lesions in rats. Arzneimittelforschung. 1984;34(9):1007-10. PubMed PMID: 6542368.
16: Crémieux G, Serratrice G. [The present treatment of headaches (author's transl)]. Sem Hop. 1978 Oct 18-25;54(33-36):1055-8. French. PubMed PMID: 35831.
17: Florence J. [Clinical study of oxetorone in catamenial migraine. Comparison of two posological diagrams (author's transl)]. Schweiz Rundsch Med Prax. 1978 Sep 5;67(36):1323-7. French. PubMed PMID: 683962.
18: Dufresne JJ. [Double-blind study of oxetorone in patients with migraine or migrainous headache (author's transl)]. Schweiz Rundsch Med Prax. 1978 Aug 1;67(31):1148-52. German. PubMed PMID: 674095.
19: Rossi E, De Pascale A, Negrini P, Zanol M, Frigerio A. Oxetorone metabolism in vitro. J Chromatogr. 1978 May 11;152(1):228-3. PubMed PMID: 649745.
20: Wasserfallen JM. [Double-blind study with oxetorone in cephalalgia (author's transl)]. Schweiz Rundsch Med Prax. 1976 Aug 17;65(33):1021-4. French. PubMed PMID: 794862.
